Sparstolonin B is primarily recognized for its anti-inflammatory properties, making it a potential therapeutic agent in managing inflammatory diseases. It has shown efficacy in inhibiting the activation of TLR2 and TLR4, which are key receptors involved in the inflammatory response. This makes it a promising candidate for treating conditions like sepsis, atherosclerosis, and other inflammatory disorders. Additionally, research suggests its potential in alleviating neuroinflammation, which could be beneficial in neurodegenerative diseases such as Alzheimer's and Parkinson's. Its ability to modulate inflammatory pathways without significant toxicity further enhances its appeal for future drug development.